DoW Multiple Sclerosis Clinical Trial Award

The DoW Multiple Sclerosis Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of multiple sclerosis. The award has two funding levels: Funding Level 1 supports small-scale, proof-of-principle clinical trials, while Funding Level 2 supports larger-scale clinical trials at phase 1 or phase 2. The clinical trials may evaluate promising new products, pharmacologic agents, devices, clinical guidance, and/or emerging approaches and technologies. Key aspects of the award include: • The award is for clinical trials that address at least one of the FY26 MSRP CTA focus areas. • Preliminary data relevant to the proposed clinical trial are required. • The award has an estimated funding of $4,000,000 and the agency expects to make 3 awards. • The opportunity is open to any type of entity, subject to any clarification in the text field entitled "Additional Information on Eligibility".